Insider’s View: Deciphering PTC Therapeutics Inc (PTCT)’s Financial Health Through Ratios

Those aiming for above-average market returns often engage in the meticulous process of stock picking. Choosing the right stocks can make a substantial difference in your wealth.

3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free
Sponsored

The price of PTC Therapeutics Inc (NASDAQ: PTCT) closed at $45.11 in the last session, down -1.96% from day before closing price of $46.01. In other words, the price has decreased by -$1.96 from its previous closing price. On the day, 0.79 million shares were traded. PTCT stock price reached its highest trading level at $47.23 during the session, while it also had its lowest trading level at $44.2011.

Ratios:

We take a closer look at PTCT’s different ratios to gain a better understanding of the stock. For the most recent quarter (mrq), Quick Ratio is recorded 2.04 and its Current Ratio is at 2.10.

On September 04, 2024, Robert W. Baird started tracking the stock assigning a Outperform rating and target price of $44.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Jul 16 ’24 when Gravier Pierre sold 2,269 shares for $34.02 per share. The transaction valued at 77,200 led to the insider holds 53,531 shares of the business.

ZELDIS JEROME B sold 20,000 shares of PTCT for $764,800 on May 22 ’24. The Director now owns 14,500 shares after completing the transaction at $38.24 per share. On May 07 ’24, another insider, Golden Lee Scott, who serves as the EVP & CHIEF MEDICAL OFFICER of the company, sold 175 shares for $32.82 each. As a result, the insider received 5,744 and left with 59,813 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, PTCT now has a Market Capitalization of 3479113472 and an Enterprise Value of 4937986048. For the stock, the TTM Price-to-Sale (P/S) ratio is 3.79. Its current Enterprise Value per Revenue stands at 5.483 whereas that against EBITDA is 226.015.

Stock Price History:

Over the past 52 weeks, PTCT has reached a high of $47.24, while it has fallen to a 52-week low of $20.75. The 50-Day Moving Average of the stock is 13.08%, while the 200-Day Moving Average is calculated to be 33.08%.

Shares Statistics:

According to the various share statistics, PTCT traded on average about 737.54K shares per day over the past 3-months and 773190 shares per day over the past 10 days. A total of 75.71M shares are outstanding, with a floating share count of 74.50M. Insiders hold about 3.40% of the company’s shares, while institutions hold 101.74% stake in the company. Shares short for PTCT as of 1731628800 were 4673031 with a Short Ratio of 6.34, compared to 1728950400 on 4658626. Therefore, it implies a Short% of Shares Outstanding of 4673031 and a Short% of Float of 9.43.

Most Popular